SABCS 2023: Pembrolizumab Improves Response in Early-Stage ER-Positive/HER2-Negative Breast Cancer
Addition of pembrolizumab to chemotherapy achieved response across patient subgroups
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.